HUP0400006A2 - Antineopláziás kombinációs készítmények - Google Patents

Antineopláziás kombinációs készítmények

Info

Publication number
HUP0400006A2
HUP0400006A2 HU0400006A HUP0400006A HUP0400006A2 HU P0400006 A2 HUP0400006 A2 HU P0400006A2 HU 0400006 A HU0400006 A HU 0400006A HU P0400006 A HUP0400006 A HU P0400006A HU P0400006 A2 HUP0400006 A2 HU P0400006A2
Authority
HU
Hungary
Prior art keywords
antineoplastic combinations
antineoplastic
combinations
Prior art date
Application number
HU0400006A
Other languages
English (en)
Hungarian (hu)
Inventor
Gary Dukart
James Joseph Gibbons Jr.
Original Assignee
Wyeth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth filed Critical Wyeth
Publication of HUP0400006A2 publication Critical patent/HUP0400006A2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HU0400006A 2001-06-01 2002-05-29 Antineopláziás kombinációs készítmények HUP0400006A2 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29523601P 2001-06-01 2001-06-01
US29519001P 2001-06-01 2001-06-01
PCT/US2002/016737 WO2002098416A2 (en) 2001-06-01 2002-05-29 Antineoplastic combinations

Publications (1)

Publication Number Publication Date
HUP0400006A2 true HUP0400006A2 (hu) 2004-04-28

Family

ID=26968972

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0400006A HUP0400006A2 (hu) 2001-06-01 2002-05-29 Antineopláziás kombinációs készítmények

Country Status (17)

Country Link
EP (1) EP1392286A2 (enExample)
JP (1) JP2004532883A (enExample)
KR (1) KR100875611B1 (enExample)
CN (1) CN100496485C (enExample)
AU (2) AU2002259309B2 (enExample)
BR (1) BR0210101A (enExample)
CA (1) CA2447732A1 (enExample)
CO (1) CO5540294A2 (enExample)
EA (1) EA007530B1 (enExample)
HU (1) HUP0400006A2 (enExample)
IL (1) IL158800A0 (enExample)
MX (1) MXPA03010907A (enExample)
NO (1) NO20035317L (enExample)
NZ (1) NZ529877A (enExample)
PL (1) PL367267A1 (enExample)
SG (1) SG153647A1 (enExample)
WO (1) WO2002098416A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2762140B1 (en) 2001-02-19 2017-03-22 Novartis AG Treatment of solid brain tumours with a rapamycin derivative
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
AR046194A1 (es) 2003-11-04 2005-11-30 Mayo Foundation Metodo de tratamiento del linfoma de celulas del manto
ZA200706804B (en) 2005-02-03 2008-10-29 Gen Hospital Corp Method for treating gefitinib resistant cancer
CA2626326C (en) * 2005-11-04 2021-02-16 Wyeth Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
EP2275103B1 (en) * 2005-11-21 2014-04-23 Novartis AG mTOR inhibitors in the treatment of endocrine tumors
GB0523658D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
US20090023768A1 (en) * 2006-02-24 2009-01-22 Novartis Ag Rapamycin derivatives for treating neuroblastoma
CN102671196B (zh) 2006-04-05 2014-12-03 诺华股份有限公司 用于治疗癌症的治疗剂的组合
CA3201293A1 (en) * 2007-03-07 2008-09-12 Abraxis Bioscience, Llc Nanoparticle comprising rapamycin and albumin as anticancer agent
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
DK2310011T3 (da) 2008-06-17 2013-10-14 Wyeth Llc Antineoplastiske kombinationer indeholdende hki-272 og vinorelbin
CA2730715C (en) 2008-08-04 2013-10-01 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
KR20140036332A (ko) 2009-04-06 2014-03-25 와이어쓰 엘엘씨 네라티닙을 이용한 유방암의 치료법
CN103721189A (zh) * 2013-12-27 2014-04-16 刘玉含 一种脑膜瘤护理药物及其制备方法
CN105168204A (zh) * 2015-09-06 2015-12-23 江志鑫 一种含有丝裂霉素的抗结肠癌药物组合物
CN119732959A (zh) * 2024-12-31 2025-04-01 吉林大学 具有mTOR抑制能力的制剂在制备抗肿瘤联合用药物组合物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5066493A (en) * 1978-11-03 1991-11-19 American Home Products Corporation Rapamycin in treatment of tumors
US4401653A (en) * 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
DK0525960T3 (da) * 1991-06-18 1996-04-15 American Home Prod Anvendelse af rapamycin til behandling af T-celle leukæmi/lymfon
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
EP2762140B1 (en) * 2001-02-19 2017-03-22 Novartis AG Treatment of solid brain tumours with a rapamycin derivative

Also Published As

Publication number Publication date
BR0210101A (pt) 2004-06-08
IL158800A0 (en) 2004-05-12
CN100496485C (zh) 2009-06-10
WO2002098416A3 (en) 2003-03-13
CO5540294A2 (es) 2005-07-29
KR20040025923A (ko) 2004-03-26
WO2002098416A2 (en) 2002-12-12
EA007530B1 (ru) 2006-10-27
AU2002259309B2 (en) 2008-05-01
EA200301319A1 (ru) 2004-04-29
CA2447732A1 (en) 2002-12-12
SG153647A1 (en) 2009-07-29
NO20035317L (no) 2003-12-22
NO20035317D0 (no) 2003-11-28
AU2008202690A1 (en) 2008-07-10
JP2004532883A (ja) 2004-10-28
KR100875611B1 (ko) 2008-12-24
MXPA03010907A (es) 2004-02-17
CN1646120A (zh) 2005-07-27
PL367267A1 (en) 2005-02-21
EP1392286A2 (en) 2004-03-03
NZ529877A (en) 2006-08-31

Similar Documents

Publication Publication Date Title
IL159859A0 (en) Antineoplastic combinations
IL160851A0 (en) Thiopene-and thiazolesulfonamides as antineoplastic agents
ZA200603888B (en) Antineoplastic combinations
IL158800A0 (en) Antineoplastic combinations
EP1417203A4 (en) S-6-HYDROXY-BUSPIRONE
AU2002360430A8 (en) 14-methyl-epothilones
DE60226167D1 (en) Computersystem-e/a-knoten
DE50201028D1 (en) Diarylgelbpigmentpraeparationen
GB0105113D0 (en) Punchbag
GB0109311D0 (en) Valcomp
EP1355643A4 (en) EPOXYVIBSANIN B
CA93127S (en) Tilt-latch
CA93647S (en) Fauteuil
HK1060846A (en) Antineoplastic combinations
GB0126276D0 (en) Macolides
GB0112702D0 (en) Sticki-strips
AU146102S (en) Bed-settee
GB0100053D0 (en) Xfercard
GB0101272D0 (en) Aquaneo
AU144891S (en) Cupboard-sideboard
GB0111098D0 (en) Gensoflex centrebar
GB0118810D0 (en) Demshute
GB0118530D0 (en) Bin-hive
GB0117988D0 (en) Karricart-kc2000
GB0116527D0 (en) Stoppabark

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees